• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic study for development of novel anti-dementia drug which selectively targets BRI2/3-ubiquitin ligase

Research Project

Project/Area Number 18K06959
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 49010:Pathological biochemistry-related
Research InstitutionKochi University

Principal Investigator

Aso Teijiro  高知大学, 教育研究部医療学系基礎医学部門, 教授 (20291289)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords認知症 / アルツハイマー病 / ユビキチンリガーゼ / NRBP1 / BRI2/ITM2 / BRI3/ITM2C / Cullin-RING ligase / Elongin / BRI2/ITM2B / BRI2 / BRI3 / Cullin RING ligase / Cullin / 認知症治療薬
Outline of Final Research Achievements

Production and fibrillation of Amyloid beta (Abeta) are down-regulated by BRI2 and BRI3, which are physiological inhibitors of amyloid precursor protein (APP) processing and Abeta oligomerization. Here, we identify NRBP1 as a substrate receptor of a Cullin-RING ubiquitin ligase (CRL) that targets BRI2 and BRI3 for degradation. Moreover, we demonstrate that (i) dimerized NRBP1 assembles into a functional Cul2- and Cul4A-containing heterodimeric CRL through its BC-box and an overlapping cryptic H-box, (ii) both Cul2 and Cul4A contribute to NRBP1 CRL function, and (iii) formation of the NRBP1 heterodimeric CRL is strongly enhanced by chaperone-like function of TSC22D3 and TSC22D4. NRBP1 knockdown in neuronal cells resulted in an increase in the abundance of BRI2 and BRI3, and significantly reduced Abeta production. Thus, disrupting interactions between NRBP1 and its substrates BRI2 and BRI3 may provide a useful therapeutic strategy for AD.

Academic Significance and Societal Importance of the Research Achievements

学術的意義:NRBP1のBC-boxに重複してDDB1の結合配列H-boxが存在することを見出し、ホモ二量体化したNRBP1がBC-box、H-boxを介してそれぞれCul2、Cul4Aと結合、ヘテロ二量体構造のCullin-RING型E3を形成することを世界で初めて示した。さらに、①基質の高度のUb化に当該E3の非対称な構造が有利に働くこと、②他の多くの基質認識タンパク質のBC-boxにもH-boxが重複して存在することを示した。
社会的意義:NRBP1とBRI2/BRI3間の相互作用の阻害は、両因子機能の人為的な活性化に繋がり、アルツハイマー病に対する根本治療薬の開発に資する可能性を示した。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (6 results)

All 2020 2019 Other

All Int'l Joint Research (2 results) Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results) Remarks (2 results) Patent(Industrial Property Rights) (1 results)

  • [Int'l Joint Research] Stowers Institute(米国)

    • Related Report
      2019 Research-status Report
  • [Int'l Joint Research] Stowers Institute(米国)

    • Related Report
      2018 Research-status Report
  • [Journal Article] NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation2020

    • Author(s)
      Yasukawa T, Tsutsui A, Tomomori-Sato C, Sato S, Saraf A, Washburn MP, Florens L, Terada T, Shimizu K, Conaway RC, Conaway JW, Aso T.
    • Journal Title

      Cell Reports

      Volume: 30 Issue: 10 Pages: 3478-3491

    • DOI

      10.1016/j.celrep.2020.02.059

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Remarks]

    • URL

      http://www.kochi-u.ac.jp/information/2020031300014/

    • Related Report
      2020 Annual Research Report
  • [Remarks]

    • URL

      http://www.kochi-u.ac.jp/information/2020031300014/

    • Related Report
      2019 Research-status Report
  • [Patent(Industrial Property Rights)] 認知症治療薬のスクリーニング方法2019

    • Inventor(s)
      麻生悌二郎、安川孝史
    • Industrial Property Rights Holder
      麻生悌二郎、安川孝史
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2019-088444
    • Filing Date
      2019
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi